CHK21100delC, I157T, IVS2 +IG > A, BRCA1 and BRCA2 Mutation Analysis in JF305: A Pancreatic Cancer Cell Line

Charles Ndawula Jr.^1,2*, Xueli Yang, Xiaohai Gong, Jian Jin

Laboratory of Molecular Pharmacology, School of Pharmaceutics, Jiangnan University, Wuxi, China.
Laboratory of Molecular Pharmacology, School of Pharmaceutics, Jiangnan University, Wuxi, China.

DOI: 10.4236/jbm.2014.21007                

Abstract

JF305 is a highly prolific pancreatic cancer cell line that originated from a Chinese patient. The cell line bears a functional HR double strand DNA repair mechanism but very responsive to PARP treatment a phenomenon clearly suggesting presence of an anomaly in the mechanism. Brca1, Brca2 and CHK2 proteins are very important constituents of the HR mechanism whose respective gene coding mutations are strongly associated with several cancers and are widely exploited in anticancer chemotherapy. In this current study, the BRCA1, BRCA2 gene mutation status in JF305 was determined together with the presence of 3 widely reported cancer linked CHK2 founder mutations (1100delC, I157T, IVS2 +IG > A). CHK21100delC genotype was determined using allele specific PCR, while the PCR-RFLP assay was used for I157T, IVS2 +IG > A analysis. PCR and direct sequencing were used for assessing the BRCA1 and BRCA2 gene. Results revealed that JF305 is CHK21100delC heterozygous mutant, CHK2I157T and CHK2IVS2 +IG > A wild type. Furthermore, it was observed that JF305 lacked BRCA1 and BRCA2 gene mutations. The mutation status identification of CHK2 and BRCA1/2 in JF305 provides a major milestone towards elucidating the properties of the cell line which subsequently promises to be an excellent model for evaluating the role of parp inhibitors in pancreatic cancer chemotherapy most especially in the respective cancer cell lines without BRCA1 and BRCA2 gene mutations.

Keywords

BRCA1; BRCA2; CHK21100delC; CHK2I157T; CHK2IVS2 +IG > A; Homologous Mechanism; PARP; Brca1; Brca2

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Fund WCR. http://wwwwcrf-ukorg/research/cancer_statistics/world_cancer_statistics
[2]	China’s Cancer Crisis. http://wwwchinaorgcn/2013-04/16/content_28556502htm
[3]	Parkin, D.M., Bray, F., Ferlay, J. and Pisani, P. (2001) Estimating the World Cancer Burden: Globocan 2000. International Journal of Cancer, 94, 153-156. http://dx.doi.org/10.1002/ijc.1440
[4]	Jemal, A., Siegel, R., Xu, J. and Ward, E. (2010) Cancer Statistics. A Cancer Journal for Clinicians, 60, 277-300. http://dx.doi.org/10.3322/caac.20073
[5]	Matthaios, D., Zarogoulidis, P., Balgouranidou, I., Chatzaki, E. and Kakolyris, S. (2011) Molecular Pathogenesis of Pancreatic Cancer and Clinical Perspectives. Oncology, 81, 259-272. http://dx.doi.org/10.1159/000334449
[6]	Li, X., Wang, H. and Jiang, Y. (1995) Establishment of a Human Pancreatic Adenocarcinoma Cell Line (Jf305) with p53 Expression. Chinese Journal of Cancer Research, 7, 251-254. http://dx.doi.org/10.1007/BF02672786
[7]	Murai, J., Huang, S.Y., Dar, B.B., Renaud, A., Zhang, Y., Doroshow, J.H., Ji, J., Takeda, S. and Pommier, Y. (2012) Trapping of PAPR1 and PARP2 by Clinical Parp Inhibitors. Cancer Research, 72, 5588-5599. http://dx.doi.org/10.1158/0008-5472.CAN-12-2753
[8]	Georges, N., Nicole, G.I., Marie, F., Frederique, M.C. and Vicent, F. (2003) Poly (ADP-Ribose) Polymerase (Parp-1) Is Not Involved in DNA Double Strand Break Recovery. BMC Cell Biology, 4, 7. http://dx.doi.org/10.1186/1471-2121-4-7
[9]	Wang, X.Z. and Weaver, D.T. (2011) The Ups and Downs of DNA Repair Biomarkers for PARP Inhibitor Therapies. American Journal of Cancer Research, 1, 301-327.
[10]	Henderson, B.R. (2012) The BRCA1 Breast Cancer Suppressor: Regulation of Transport, Dynamics, and Function at Multiple Subcellular Locations. Scientifica, Article ID 796808. http://dx.doi.org/10.6064/2012/796808
[11]	Hall, J.M, Lee, M.K., Newman, B., Morrow, J.E., Anderson, L.A., Huey, B. and King, M.C. (1990) Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21. Science, 250, 1684-1689. http://dx.doi.org/10.1126/science.2270482
[12]	Hofmann, W. and Schlag, P.M. (2000) BRCA1 and BRCA2—Breast Cancer Susceptibility Genes. Journal of Cancer Research and Clinical Oncology, 126, 487-496. http://dx.doi.org/10.1007/s004320000140
[13]	Carter, R.F. (2001) BRCA1, BRCA2 and Breast Cancer: A Concise Clinical Review. Clinical Investigation Medicine, 24, 147-157.
[14]	Satagopan, J.M., Offit, K., Foulkes, W., Robson, M.E., Wacholder, S., Eng, C.M., Karp, S.E. and Begg, C.B. (2001) The Lifetime Risks of Breast Cancer in Ashkenazi Jewish Carriers of BRCA1 and BRCA2 Mutations. Cancer Epide-Miology, Biomarkers &Prevention, 10, 467-473.
[15]	Peto, J., Collins, N., Barfoot, R., Seal, S., Warren, W., Rahman, N., Easton, D.F., Evans. C., Deacon, J. and Stratton, M.R. (1999) Prevalence of BRCA1 and BRCA2 Gene Mutations in Patients with Early-Onset Breast Cancer. Journal of National Cancer Institute, 91, 943-949. http://dx.doi.org/10.1093/jnci/91.11.943
[16]	http://www.ncbi.nlm.nih.gov/nuccore/U14680.1
[17]	http://www.ncbi.nlm.nih.gov/nuccore/U43746.1
[18]	Smith, T.M., Szabo, L.M., Jerome, C. I., McEuen, N., Taylor, M., Hood, M.L. and King, M.C. (1996) Complete Genomic Sequence and Analysis of 117 kb of Human DNA Containing the Gene BRCA1. Genome Research, 6, 1029-1049. http://dx.doi.org/10.1101/gr.6.11.1029
[19]	Wooster, R., Neuhausen,S.L., Mangion, J., Quirk, Y., Ford, D., Collins, N., Nguyen, K., Seal, S., Tran, T., Averill, D., et al. (1994) Localization of a Breast Cancer Susceptibility Gene, BRCA2, to Chromosome 13q12-13. Science, 265, 2088-2090. http://dx.doi.org/10.1126/science.8091231
[20]	Garvin, A.M., Attenhofer-Haner, M. and Scott, R.J. (1997) BRCA1 and BRCA2 Mutation Analysis in 86 Early Onset Breast/Ovarian Cancer Patients. Journal of Medical Genetics, 34, 990-995. http://dx.doi.org/10.1136/jmg.34.12.990
[21]	Christine, S., Jean-Paul, M., Claire, J.R., François, E., Dominique, S.L., Brigitte, B.P. and Hagay, S. (2002) Testing for BRCA1 Mutations: A Cost-Effectiveness Analysis. European Journal of Human Genetics, 10, 599-606. http://dx.doi.org/10.1038/sj.ejhg.5200854
[22]	Antoni, L., Sodha, N., Collins, I. and Garrett, M.D. (2007) CHK2 Kinase: Cancer Susceptibility and Cancer Therapy— Two Sides of the Same Coin? Nature Review Cancer, 7, 925-936. http://dx.doi.org/10.1038/nrc2251
[23]	Bayram, S., Akkiz, H. and Topaktas, M. (2013) CHK2 1100delC, IVS2+1G>A and I157T Mutations Are Not Present in Hepatocellular Cancer Cases from a Turkish Population. Gene, 512, 232-236. http://dx.doi.org/10.1016/j.gene.2012.10.045
[24]	Ahn, J., Urist, M. and Prives, C. (2004) The Chk2 Protein Kinase. DNA Repair (Amst.), 3, 1039-1047. http://dx.doi.org/10.1016/j.dnarep.2004.03.033
[25]	Bell, D.W., Varley, J.M., Szydlo, T.E., Kang, D.H., Wahrer, D.C., Shannon, K.E., Lubratovich, M.S., Verselis, J., Isselbacher, K.J., Fraumeni, J.F., Birch, J.M., Li, F.P., Garber, J.E. and Haber, D.A. (1999) Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome. Science, 286, 2528-2531. http://dx.doi.org/10.1126/science.286.5449.2528
[26]	Sodha, N., Williams, R., Mangion, J., Bullock, S.L., Yuille, M.R. and Eeles, R.A. (2000) Screening hCHK2 for Mutations. Science, 289, 359.
[27]	Shaag, A., Walsh, T., Renbaum, P., Kirchhoff, T., Nafa, K., Shiovitz, S., Mandell, J.B., Welcsh, P., Lee, M.K., Ellis, N., Offit, K., Levy-Lahad, E. and King, M.C. (2005) Functional and Genomic Approaches Reveal an Ancient CHEK2 Allele Associated with Breast Cancer in the Ashkenazi Jewish Population. Human Molecular Genetics, 14, 555-563. http://dx.doi.org/10.1093/hmg/ddi052
[28]	Cybulski, C., Gorski, B., Huzarski, T., Masojc, B., Mierzejewski, M., Debniak, T., et al. (2004) CHEK2 Is a Multiorgan Cancer Susceptibility Gene. The American Journal of Human Genetics, 75, 1131-1135. http://dx.doi.org/10.1086/426403
[29]	Cybulski, C., Huzarski, T., Górski, B., Masojc, B., Mierzejewski, M., Debniak, T., Gliniewicz, B., Matyjasik, J., Zlowocka, E., Kurzawski, G., Sikorski, A., Posmyk, M., Szwiec, M., Czajka, R., Narod, S.A. and Lubiński, J. (2004) A Novel Founder CHEK2 Mutation Is Associated with Increased Prostate Cancer Risk. Cancer Research, 64, 2677-2679. http://dx.doi.org/10.1158/0008-5472.CAN-04-0341
[30]	Cybulski, C., Wokolorczyk, D., Huzarski, T., Byrski, T., Gronwald, J., Górski, B., Debniak, T., Masojc, B., Jakubowska, A., Gliniewicz, B., Sikorski, A., Stawicka, M., Godlewski, D., Kwias, Z., Antczak, A., Krajka, K., Lauer, W., Sosnowski, M., Sikorska-Radek, P., Bar, B., Klijer, R., Zdrojowy, R., Malkiewicz, B., Borkowski, A., Borkowski, T., Szwiec, M., Narod, S.A. and Lubiński, J. (2006) A Large Germline Deletion in the Chek2 Kinase Gene Is Associated with an Increased Risk of Prostate Cancer. Journal of Medical Genetics, 43, 863-866. http://dx.doi.org/10.1136/jmg.2006.044974
[31]	Meijers-Heijboer, H., Van den, A., Klijn, M., Wasielewski, J., de Snoo., A., Oldenburg, R., Hollestelle, A., Houben, M., Crepin, E., van Veghel-Plandsoen, M., Elstrodt, F., van Duijn, C., Bartels, C., Meijers, C., Schutte, M., McGuffog, L., Thompson, D., Easton, D., Sodha, N., Seal, S., Barfoot, R., Mangion, J., Chang-Claude, J., Eccles, D., Eeles, R., Evans, D.G., Houlston, R., Murday, V., Narod, S., Peretz, T., Peto, J., Phelan, C., Zhang, H.X., Szabo, C., Devilee, P., Goldgar, D., Futreal, P.A., Nathanson, K.L., Weber, B., Rahman, N. and Stratton, M.R. (2002) Low-Penetrance Susceptibility to Breast Cancer Due to CHEK2(*)1100delC in Noncarriers of BRCA1 or BRCA2 Mutations. Nature Genetics, 31, 55-59. http://dx.doi.org/10.1038/ng879
[32]	Dong, X.Y., Wang, L., Ken, T., Wang, X.S., Julie, M., Cunningham, M., McDonnell, S.K., Chiping, Q., Angela, F., Marks, S., Susan, L.S., Peterson, B.J., Smith, D.I., Cheville, J.C., Blute, M.L., Jacobsen, S.J., Schaid, D.J., Tindall, D.J., Thibodeau, S.N. and Liu, W. (2003) Mutations in CHEK2 Associated with Prostate Cancer Risk. The American Journal of Human Genetics, 72, 270-280. http://dx.doi.org/10.1086/346094
[33]	Kleibl, Z., Havranek, O., Novotny, J., Kleiblova, P., Soucek, P. and Pohlreich, P. (2008) Analysis of CHEK2 FHA Domain in Czech Patients with Sporadic Breast Cancer Revealed Distinct Rare Genetic Alterations. Breast Cancer Research and Treatment, 112, 159-164. http://dx.doi.org/10.1007/s10549-007-9838-7
[34]	Cybulski, C., Górski, B., Huzarski, T., Masojc, B., Mierzejewski, M., Debniak, T., Teodorczyk, U., Byrski, T., Gronwald, J., Matyjasik, J., Zlowocka, E., Lenner, M., Grabowska, E., Nej, K., Castaneda, J., Medrek, K., Szymańska, A., Szymańska, J., Kurzawski, G., Suchy, J., Oszurek, O., Witek, A., Narod, S.A. and Lubiński, J. (2004) CHEK2 Is a Multiorgan Cancer Susceptibility Gene. The American Journal of Human Genetics, 75, 1131-1135. http://dx.doi.org/10.1086/426403
[35]	Matsuoka, S., Nakagawa, T., Masuda, A., Haruki, N., Elledge, S.J. and Takahashi, T. (2001) Reduced Expression and Impaired Kinase Activity of a Chk2 Mutant Identified in Human Lung Cancer. Cancer Research, 61, 5362-5365.
[36]	Sodha, N., Richard, S.H., Richard, W., Martin, A.Y., John, M. and Rosalind, A.E. (2002) A Robust Method for Detecting CHK2/RAD53 Mutations in Genomic DNA. Humanmutation, 19, 173-177. http://dx.doi.org/10.1002/humu.10031
[37]	Djureinovic, T., Lindblom, A., Dalén, J., Dedorson, S., Edler, D., Hjern, F., Holm, J., Lenander, C., Lindforss, U., Lundqvist, N., Olivecrona, H., Olsson, L., Påhlman, L., Rutegård, J., Smedh, K., Törnqvist, A., Eiberg, H. and Bisgaard, M.L. (2006) The CHEK2 1100delC Variant in Swedish Colorectal Cancer. Anticancer Research, 26, 4885-4888.
[38]	Bayram, S., Akkiz, H. and Topaktas, M. (2013) CHK2 1100delC, IVS2+1G>A and I157T Mutations Are Not Present in Hepatocellular Cancer Cases from a Turkish Population. Gene, 512, 232-236. http://dx.doi.org/10.1016/j.gene.2012.10.045
[39]	Garvin, A.M. (1998) A Complete Protein Truncation Test for BRCA1 and BRCA2. European Journal of Human Genetics, 6, 226-234. http://dx.doi.org/10.1038/sj.ejhg.5200172
[40]	Ottini, L., D’Amico, C., Noviello, C., Lauro, S., Lalle, M., Fornarini, G., Colantuoni, O.A., Pizzi, C., Cortesi, E., Carlini, S., Guadagni, F., Bianco, A.R., Frati, L., Contegiacomo, A. and Mariani-Costantini, R. (2000) BRCA1 and BRCA2 Mutations in Central and Southern Italian Patients. Breast Cancer Reserch, 22, 307-310. http://dx.doi.org/10.1186/bcr72
[41]	Cybulski, C., Górski, B., Huzarski, T., Masojc, B., Mierzejewski, M., Debniak, T., Teodorczyk, U., Byrski, T., Gronwald, J., Matyjasik, J., Zlowocka, E., Lenner, M., Grabowska, E., Nej, K., Castaneda, J., Medrek, K., Szymańska, A., Szymańska, J., Kurzawski, G., Suchy, J., Oszurek, O., Witek, A., Narod, S.A. and Lubiński, J. ( 2004) CHEK2 Is a Multiorgan Cancer Susceptibility Gene. The American Journal of Human Genetics, 75, 1131-1135. http://dx.doi.org/10.1086/426403